Company Encyclopedia
View More
name
China SXT Pharmaceuticals
SXTC.US
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
4.362 T
SXTC.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking141/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-22.50%E
    • Profit Margin-189.77%E
    • Gross Margin21.11%D
  • Growth ScoreD
    • Revenue YoY-9.73%D
    • Net Profit YoY-6.62%C
    • Total Assets YoY-6.33%D
    • Net Assets YoY10.83%B
  • Cash ScoreD
    • Cash Flow Margin-52.70%D
    • OCF YoY-9.73%D
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreB
    • Gearing Ratio28.73%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chinese Stocks To Consider - November 19th

    MarketBeat's stock screener tool highlights Diageo, UP Fintech, and China SXT Pharmaceuticals as key Chinese stocks to watch. Diageo engages in alcoholic beverage production, UP Fintech offers online brokerage services, and China SXT Pharmaceuticals focuses on traditional Chinese medicine. These stocks have high trading volumes recently. MarketBeat provides insights into top-rated stocks, though Diageo is not among the top five recommended by analysts.

    Market Beat·
    US
    DEO
    +3.69%
    US
    SXTC
    +1.86%
    US
    TIGR
    +4.44%
    Market Beat·
    US
    DEO
    +3.69%
    US
    SXTC
    +1.86%
    US
    TIGR
    +4.44%

    Best Chinese Stocks To Watch Today - November 15th

    MarketBeat's stock screener tool highlights five Chinese stocks to watch: Diageo, UP Fintech, Regencell Bioscience, RBB Bancorp, and China SXT Pharmaceuticals. These companies have shown high trading volumes recently. The report provides insights into each company's operations and market focus, emphasizing their potential as investment opportunities. Despite Diageo's Hold rating, analysts suggest the other four stocks as better buys. The news aims to guide investors on promising Chinese stocks amidst economic and geopolitical factors.

    Market Beat·
    US
    SXTC
    +1.86%
    Market Beat·
    US
    SXTC
    +1.86%

    Chinese Stocks To Follow Today - November 12th

    MarketBeat's stock screener tool highlights five Chinese stocks to watch today: Diageo, UP Fintech, Regencell Bioscience, China SXT Pharmaceuticals, and Baiya International Group. These companies have the highest dollar trading volume among Chinese stocks recently. They operate in various sectors including alcoholic beverages, online brokerage, traditional Chinese medicine, and pharmaceuticals.

    Market Beat·
    US
    SXTC
    +1.86%
    US
    BIYA
    -3.60%
    US
    RGC
    -1.11%
    Market Beat·
    US
    SXTC
    +1.86%
    US
    BIYA
    -3.60%
    US
    RGC
    -1.11%

    China SXT Pharmaceuticals (NASDAQ:SXTC) Given "Sell (E+)" Rating at Weiss Ratings

    Weiss Ratings has reaffirmed a "sell (e+)" rating for China SXT Pharmaceuticals (NASDAQ:SXTC) in a recent report. The stock traded down to $1.56, with an average rating of "sell" from analysts. Despite a recent upgrade from Wall Street Zen to a "hold" rating, the company has a debt-to-equity ratio of 0.01 and a current ratio of 3.54. The stock has fluctuated between a low of $0.95 and a high of $7.84 over the past year.

    Market Beat·
    US
    SXTC
    +1.86%
    Market Beat·
    US
    SXTC
    +1.86%

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    In Wednesday's after-market session, several health care stocks saw significant movements. PepGen (PEPG) shares surged by 43.8% to $3.84, with a market value of $63.9 million. Immuneering (IMRX) shares rose by 37.59% to $12.7, valued at $357.0 million. Qualigen Therapeutics (QLGN) increased by 17.14% to $4.85, with a market cap of $7.0 million. Other notable gainers included China SXT Pharmaceuticals (SXTC) up 9.49% to $1.73, Jasper Therapeutics (JSPR) up 7.72% to $2.51, and Liminatus Pharma (LIMN) up 5.59% to $1.51. The article was generated by Benzinga's automated content engine and reviewed by an editor.

    Benzinga·
    US
    SXTC
    +1.86%
    US
    QLGN
    0.00%
    US
    JSPR
    -3.41%
    Benzinga·
    US
    SXTC
    +1.86%
    US
    QLGN
    0.00%
    US
    JSPR
    -3.41%